Posted in Regulatory Travere wins long-awaited approval for kidney disease drug April 15, 2026 BioPharma Dive The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity believed to be worth more than $1 billion annually. RegulatoryRare DiseaseRead full story